Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Byron Albertson

Pediatrics Benton, KY Doctor of Osteopathy

NPI 1346228467 CMS profile 197524

83 Wellness Way Ste 101&201, Benton, KY 42025

Open in the dashboard

General payments

$7,334

527 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Byron Albertson of Benton, KY is reported in the CMS Open Payments database as having received $7,334 across 527 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Pediatrics profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $58 3
2023 General $1,750 117
2022 General $1,183 79
2021 General $1,353 96
2020 General $1,014 79
2019 General $1,975 153

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Byron Albertson
  • Pediatrics median
  • Middle half of Pediatrics
  • National median

In program year 2025, general payments to Byron Albertson were reported at $58. Among 22,296 Pediatrics profiles paid that year, the median was $97 and the middle half received between $37 and $210.

Show as a table
Year Byron Albertson Pediatrics median Middle half National median
2019 $1,975 $86 $31–$183 $163
2020 $1,014 $49 $22–$110 $114
2021 $1,353 $68 $27–$158 $132
2022 $1,183 $77 $30–$173 $149
2023 $1,750 $88 $33–$190 $160
2024 $0 $94 $34–$206 $164
2025 $58 $97 $37–$210 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amgen Inc. $810 58 payments
  2. AbbVie, Inc. $717 48 payments
  3. Novo Nordisk Inc $580 46 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $574 41 payments
  5. Lilly USA, LLC $559 42 payments
  6. Pfizer Inc. $387 36 payments
  7. GlaxoSmithKline, LLC. $381 32 payments
  8. Janssen Pharmaceuticals, Inc $373 29 payments
  9. Otsuka America Pharmaceutical, Inc. $299 18 payments
  10. Allergan Inc. $277 27 payments
  11. Other $2,378 150 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,292 523 payments
  2. Education $42 4 payments
Products named General payments · program years 2019–2025
  1. Repatha $454 35 payments
  2. Ozempic $395 31 payments
  3. JARDIANCE Diabetes $391 27 payments
  4. XARELTO $341 27 payments
  5. TRULICITY $332 25 payments
  6. VRAYLAR $300 20 payments
  7. JARDIANCE Diabetes $299 22 payments
  8. REXULTI $299 18 payments
  9. EVENITY $294 19 payments
  10. AIMOVIG $280 21 payments
  11. Other $6,683 514 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 205 drugs

Part D claims

13,394

Median for Internal Medicine: 777

Drug cost

$1,445,619

Median for Internal Medicine: $73,373

Branded share of claims

22.4%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 111 $180,619
Jardiance Empagliflozin Brand 102 $118,588
Mounjaro Tirzepatide Brand 81 $110,651
Eliquis Apixaban Brand 91 $86,754
Farxiga Dapagliflozin Propanediol Brand 87 $71,377
Vraylar Cariprazine Hcl Brand 41 $56,458
Soliqua 100-33 Insulin Glargine/Lixisenatide Brand 38 $47,560
Trulicity Dulaglutide Brand 33 $43,406
Repatha Sureclick Evolocumab Brand 41 $39,051
Januvia Sitagliptin Phosphate Brand 40 $33,846

The 10 drugs with the highest cost, of 205 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 43 billing codes

Paid by Medicare

$77,567

Of which drugs: $2,873

Medicare patients

248

Average age 75

Services billed

1,793

109 women, 139 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 52%
Diabetes 30%
Ischemic heart disease 27%
Chronic kidney disease 26%
Depression 25%
COPD 23%
Atrial fibrillation 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 29 29 $2,373
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 15 74 $47

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

527 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatrics in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record